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Skeletal muscle protein turnover is modulated by intracellular signaling pathways involved in protein synthesis, degradation,
and inﬂammation. The proinﬂammatory status of muscle cells, observed in pathological conditions such as cancer, aging, and
sepsis, can directly modulate protein translation initiation and muscle proteolysis, contributing to negative protein turnover. In
this context, branched-chain amino acids (BCAAs), especially leucine, have been described as a strong nutritional stimulus able
to enhance protein translation initiation and attenuate proteolysis. Furthermore, under inﬂammatory conditions, BCAA can be
transaminated to glutamate in order to increase glutamine synthesis, which is a substrate highly consumed by inﬂammatory cells
such as macrophages. The present paper describes the role of inﬂammation on muscle remodeling and the possible metabolic and
cellular eﬀects of BCAA supplementation in the modulation of inﬂammatory status of skeletal muscle and the consequences on
protein synthesis and degradation.
1.Introduction
Skeletal muscle presents unique features that allow it to
respond to several exogenous stimuli. This characteristic is
named “plasticity” [1]. Exercise and nutrition are examples
of such stimuli that may promote adaptive responses in
skeletal muscle in terms of structure and function [2–4]. For
example, there are some reports describing that mechanical
stimuli, particularly resistance exercise, may induce histo-
logical changes such as ﬁber type transition and proﬁle
and increase in cross-sectional area [5], and alterations
in muscle function [6, 7]. Branched-chain amino acids
(BCAA), especially leucine, are also well-known nutrients
that may inﬂuence the adaptive response of skeletal muscle.
Leucine supplementation has been described as a potential
nonpharmacological tool able to stimulate both muscle
anabolism and decrease catabolism [8, 9]a n dt om o d u l a t e
glucose homeostasis [10]. Furthermore, leucine can act syn-
ergistically with exercise to improve the eﬃciency and effect-
iveness of these adaptive responses [11].
Currently, there are some cellular pathways that partially
explain why BCAA supplementation may promote such re-
sponsesinskeletalmuscle.Mostoftheseconsistentevidences
were observed on incubated cells, which have contributed
to elucidate important mechanisms regarding amino acids
modulationofskeletal muscleproteinturnover.However,we
have to consider that such conditions are considerably diﬀer-
ent from the human body. Although experimental animals2 J o u r n a lo fN u t r i t i o na n dM e t a b o l i s m
(rodents) represent an in vivo model, it may also present dis-
tinct results when compared to humans. Recently, our group
observed that due to diﬀerences in muscle metabolism,
rodentsmayresponddiﬀerentlyfromhumanstoaminoacids
supplementation [12]. Although the same signaling path-
ways are found in rodent and human cells the response of
these models to amino acids supplementation present indi-
vidualities that may compromise the extrapolation of results.
The mammalian target of rapamycin (mTOR) pathway
is a signal-dependent cascade that responds to a variety
of stimuli ranging from growth factors and mitogens to
amino acid deprivation and hypoxic stress. It has been well
characterized that mTOR pathway has a pivotal role in
modulatingproteintranslationinitiationthrougheukaryotic
initiation factors (eIFs) and kinases, which in turn alter the
phosphorylation status and activity of several proteins in
this cellular pathway [13]. Amino acids supplementation
is involved in signaling to upstream proteins, responsible
for sensing and triggering (mTOR, human vacuolar protein
sorting 34 (hVps4), calcium-related proteins) [14], as well
as downstream proteins, responsible for ribosome initiation
complex formation (eIF4E, eIF4E-binding protein 1 (4E-
BP1), eIF4F complex) [15, 16]. Additionally, it has been
shown that BCAA can also interact with the proteolytic
machinery (ubiquitin proteasome system—UPS) in order to
attenuate muscle wasting [17]. This response may partially
involve the protein kinase Akt/PKB, which also participates
in glucose homeostasis and muscle hypertrophy. Regarding
the proteolytic machinery, Akt/PKB is known to phospho-
rylate the transcription factor forkhead box class-O (FoxO),
which translates the two majority genes (or E3 ligases) of
muscle atrophy: atrogin-1 and muscle RING-ﬁnger protein-
1( M u R F - 1 )[ 12, 18, 19], to phosphorylate mTOR and stim-
ulate protein synthesis, and to modulate glucose transporter
4 (GLUT4) to the sarcolemma [20]. In view of this, these
cellularpathways(synthesisanddegradation)arenotdistinct
and may be controlled by amino acids through indirect
genomic and nongenomic actions.
Although much attention has been given to the role of
amino acids in these pathways, the responsiveness of skeletal
muscletothesenutrientsmaybelimited.Forinstance,amino
acids infusion stimulate muscle protein accretion until it
reaches a plateau [21]. This condition, known as “anabolic
resistance to amino acids”—the inability of skeletal muscle
to maintain or increase its protein mass by appropriate
nutritional stimulation [22] occurs because skeletal muscle
protein synthesis is refractory to hyperaminoacidemia. Thus,
it appears that the optimal action of amino acids on skeletal
muscle growth occur in combination with other exogenous
stimuli (e.g., exercise) or in situations characterized by dis-
ruptionoforganichomeostasis(e.g.,cancer,diabetes,muscle
disuse, sepsis, chronic heart failure). In this context, the
inﬂammatory status has a considerable role and the innate
immune system (responsible for cytokines and chemokines
production) should be carefully considered.
The focus of this paper is to discuss the possible
metabolic and cellular roles of BCAA supplementation on
the inﬂammatory status of skeletal muscle and the eﬀects
on protein synthesis and degradation. It is possible that, in
some conditions, the administration of these amino acids
could exert an anti-inﬂammatory role or indirectly modulate
the inﬂammatory status and balance of the system and/or
the muscle cell in order to favor the biological response and
tissue adaptation.
2. The Role of InﬂammationinSkeletal Muscle
The healing of injured muscle is composed of sequential but
overlappedphasesofinjury,inﬂammation,regeneration,and
ﬁbrosis. Injury and inﬂammation predominate the ﬁrst few
days after injury, followed by regeneration. When there is a
severe injury the muscle does not recover completely and
forms ﬁbrotic tissue approximately two weeks after injury
[23]( Figure 1).
The inﬂammatory response is an important phase of the
natural healing process. During this phase there is a release
of several types of cytokines and growth factors to increase
the permeability of blood vessels and chemotaxis of inﬂam-
matory cells, such as neutrophils and macrophages. These
cells contribute to the degradation of damaged muscle tissue
by releasing reactive oxygen species (ROS) and producing
proinﬂammatory cytokines [24–27] such as tumor necrosis
factor alpha (TNF-α), interleukin-1 (IL-1), and IL-6 that
regulate the inﬂammatory process [28, 29]. The role of these
cells is quite complex and they can promote both injury and
repair. A detailed discussion of their action is beyond the
scope of this paper and has been reviewed elsewhere [30].
2.1. Tumor Necrosis Factor Alpha (TNF-α). Some systemic
inﬂammatorycytokinessuchasTNF-αandIL-1β havedirect
catabolic eﬀects on skeletal muscle. The cytokine TNF-α
plays a key role in the skeletal muscle wasting present in
chronic diseases, such as cancer, sepsis, and rheumatoid
arthritis, conditions in which a raise in the plasma TNF-α
concentration have been described [27, 31]. TNF-α impairs
muscle protein synthesis [32, 33] by destabilizing myogenic
diﬀerentiation and altering transcriptional activity [34]a n d
increases muscle loss [35, 36] by targeting proteins to the
ubiquitin-proteasome- mediated degradation pathway [37–
39]. TNF-α has also an eﬀect on satellite cells and muscle
regeneration. In vitro studies have shown that exposure of
myoblasts to TNF-α inhibits their diﬀerentiation [40, 41].
The release of ROS induced by TNF-α induces degradation
of the inhibitor-κB( I κB), which allows the nuclear factor-
kappaB (NF-κB) to translocate to the nucleus and to activate
the transcription of several κB-dependent genes such as
those encoding proinﬂammatory cytokines, and breakdown
of MyoD and myogenin (regulators of the transition from
proliferation to diﬀerentiation) in the proteasome [34].
Although most research has focused on the muscle wast-
ing eﬀects of TNF-α, under speciﬁc conditions this cytokine
can also promote muscle protein synthesis and stimulate
satellitecellproliferationanddiﬀerentiation[38,42].Among
the factors that mediate the diﬀerent eﬀects of TNF-α
on protein synthesis or degradation are the state of cell
diﬀerentiation and the concentration of TNF-α. Chen et al.
[42] have shown that the eﬀects of TNF-α on myogenesisJ o u r n a lo fN u t r i t i o na n dM e t a b o l i s m 3
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Figure 1: Signaling pathways linking skeletal muscle inﬂammation and remodeling Possible role of BCAA action. Skeletal muscle
inﬂammation can increase the expression and activity of factors such as TNF-αB, ROS, IL-6, and NF-κB which in turn could contribute to
proteindegradationandattenuateproteinsynthesis.Ontheotherhand,BCAAsupplementationcouldcounteractsucheﬀectsbysuppressing
skeletal muscle proteolysis and stimulation protein synthesis. BCAA: branched-chain amino acids; IL-6: interleukin 6: NF-κB, nuclear factor
kappa B: ROS: reactive oxygen species; TNF-α: tumor necrosis alpha.
and muscle regeneration are concentration dependent: a low
concentration of TNF-α (0.05ng/mL) promoted the diﬀer-
entiation of cultured myoblasts while higher concentrations
(0.5 and 5ng/mL) inhibited it. Furthermore, diﬀerences in
the expression of the TNF-α receptor on the surface of diﬀer-
entcelltypesmayexplainthevariableeﬀectsofthiscytokine.
In primary myotubes, low doses of TNF-α (1ng/mL)
stimulated maximal protein synthesis, while a much higher
dose (50ng/mL) was required to stimulate maximal protein
synthesis in C2C12 myotubes [43]. Therefore, the eﬀects of
TNF-α depend on the concentration and exposure duration:
low concentrations help the repair process, while high and
prolonged exposure impairs the regeneration process. It is
possible that other factors, such as insulin growth factor 1
(IGF-1) and inﬂammatory cytokines mediate the eﬀects of
TNF-α on protein synthesis/degradation, but their roles are
still unclear [43, 44].
Elevated levels of TNF-α have also been implicated in
sarcopenia, the age-related loss of muscle mass, strength,
a n df u n c t i o n[ 45]. It is a key factor contributing to loss
of functional mobility, frailty, and mortality in the elderly
[46, 47]. Inﬂammation, which generally increases with age,
is a key factor contributing to sarcopenia, and high level
of TNF-α is partly responsible for the decrease in muscle
protein synthesis that occurs in the elderly [48–51]. Greiwe
et al. [52] have found elevated levels of TNF-α mRNA and
protein in the skeletal muscle of elderly (81 ± 1 years) when
compared to young (23 ± 1 years) men and women. The
same authors also showed that resistance exercise decreased
TNF-α expression in the elderly group, suggesting that TNF-
α contributes to the age-related muscle wasting, and that
resistance exercise may attenuate this process by suppressing
TNF-α expression.
2.2. Lipopolysaccharides (LPS). LPS are components of the
outer wall of Gram-negative bacteria. It is well known that
Gram-negative infection (or the administration of lipopol-
ysaccharides) causes loss of skeletal muscle protein. The
decrease in muscle mass results from increases in the rate of
proteolysis and decreased rates of protein synthesis [53, 54].
A decrease in mTOR activity may explain, at least in part,
the impaired muscle protein synthesis. Frost et al. [55]h a v e
shown that a combination of LPS and IFN-gamma dramati-
cally downregulated the autophosphorylation of mTOR and
itssubstratesS6K1and4E-BP1viaanincreasedexpressionof
iNOS(NOS2)andexcessiveproductionofnitricoxide(NO).
2.3. Interleukin-6 (IL-6). Studies in mice have shown that
overexpression of IL-6 may increase muscle atrophy [56].
However, under certain conditions IL-6 can also promote
muscle growth. In vitro data has shown that recombinant IL-
6 stimulates myoblasts diﬀerentiation [57]. Furthermore, Al-
Shantietal.[58]demonstratedthatIL-6incombinationwith
TNF-α stimulate growth of myoblasts. Therefore, the role of
IL-6 in regulating muscle mass appears to be concentration
dependent: when overexpressed it may stimulate muscle
atrophy, whereas its insuﬃciency inhibits muscle growth.
2.4. Nuclear Factor Kappa B (NF-κB). The NF-κBs e r v e sa s
a key responder to changes in the environment. It mainly
controls the expression of genes involved in the immune
response, but it also regulates the expression of genes outside
the immune system and is therefore able to inﬂuence several
aspects of normal and disease physiology [59, 60]. The
classic form of NF-κB, a heterodimer of the p50 and p65
subunits, is retained in the cytoplasm through interactions
with IκB inhibitory proteins. Inducing stimuli lead to the
phosphorylation and degradation of IκBb yI κB kinases
(IKK),allowingNF-κBtoenterthenucleusandregulategene
expression [61]. Chronic activation of NF-κB is related to
skeletal muscle pathology. In mice, NF-κB activation causes4 J o u r n a lo fN u t r i t i o na n dM e t a b o l i s m
severe muscle wasting [62]a n dN F - κBi sak e yf a c t o ri n
cytokine induced loss of skeletal muscle [63].
Exercise may activate several signaling cascades and
increase the production of ROS, which activate NF-κB[ 42,
64]i nm u s c l e[ 65, 66]. The exercise induced increase in NF-
κB induces acute-phase proteins and also proinﬂammatory
genes that facilitate the regenerative response in damaged
tissues. The involvement of NF-κB in muscle damage has
been shown in several reports where exhaustive exercise has
caused increases in NF-κB binding activity [67]. Roberts
et al. [68] have also shown that the inﬂammatory response to
exerciseisattenuatedbychronictraining,demonstratingthat
the activity of NF-κB can be seen as a beneﬁcial mediator of
exercise-induced adaptations to cellular stress. Furthermore,
exercise training may induce local anti-inﬂammatory eﬀects
in skeletal muscle [69].
A training program can also exert an inhibitory eﬀect
on NF-κB DNA binding [70, 71]. Regular physical training
leads to several adaptations in the vascular, oxidative, and
inﬂammatory systems, suggesting that transcriptional regu-
lators of the various nitric oxide synthase (NOS) isoforms
by NF-κB play a key role in training-induced adaptations
[72, 73]. Lima-Cabello et al. [74] have demonstrated that
the eﬀects observed after a bout of acute exercise on the
NF-κB signaling were attenuated by submaximal eccentric
exercise training for 8 weeks. Also, the levels of nNOS, iNOS
and eNOS expression and nitrotyrosine formation decreased
when compared to the acute group.
3. The Possible Role of BCAA Supplementation
on Muscle Inﬂammation
Unlike other amino acids, the most active enzyme system
for BCAA transamination is found in the skeletal muscle
rather than the liver [75] .T h eﬁ r s tr e a c t i o ni n v o l v e di nt h e
catabolism of BCAA is the reversible reaction of transami-
nation by isoenzymes BCAT (branched-chain aminotrans-
ferase) found in both cytosol and mitochondria, which con-
vert amino acids into their respective keto acids (branched-
chain keto acids—BCKA), being the α-ketoisocaproic acid
(KIC) for leucine, α-keto-β-methylvaleric acid (KMV) for
isoleucine, and α-ketoisovaleric acid (KIV) for valine. The
BCKAs formed may undergo oxidative decarboxylation
reactions and/or be released in the blood stream and taken
upbydiﬀerenttissues, wheretheyareresynthesized to BCAA
or oxidized [75]. It is well known that the amino group from
BCAA can be incorporated into the α-keto-glutarate (α-KG)
producing glutamate through glutamate dehydrogenase
(GDH). The glutamate can lose the amino group for oxalac-
etate (OAA) through glutamate-oxalacetate aminotrans-
ferase (GOT) producing aspartate to be used in the purine
cycle for regeneration of adenosine monophosphate (AMP)
from inosinic acid. Glutamate can also be metabolized
by glutamine synthetase producing glutamine through
ATP-dependent incorporation of NH+
3 [76]( Figure 2).
Muscle cells present very high concentrations of gluta-
mate and a low activity of GDH [77]. Therefore, the amino
group released from BCAA could be easily reincorporated by
BCKA (reamination) to produce BCAA or directed to the
liver to be oxidized. Alanine can also be synthetized from
BCAA since the glutamate-pyruvate aminotransferase can
produce pyruvate which can be transaminated to alanine
through pyruvate aminotransferase [78, 79]. However, this
reaction appears to occur only in situations characterized
by absence of energy (i.e., fasting) since skeletal muscle also
presents high concentrations of alanine [75].
The intracellular pool of amino acids can be derived
from biosynthesis (i.e., nonessential amino acids) or from
transfer across the plasma membrane (i.e., essential amino
acids). Transfer across biological membranes can occur
throughactive(Na2+-dependent)orpassivetransport(Na2+-
independent) due to their ionic nature [80]. In some
instances the process of transfer involves not only the entry
but exit of amino acids (exchange). The transport system of
glutamine is called System A (Na2+-dependent) and the one
of leucine is called System l (L; Na2+-independent), which
are integrated. The glutamine entry in the cell requires Na2+,
while leucine entry requires exit of glutamine. In conditions
where the requirement of glutamine is increased (i.e.,
catabolic illness), theoretically the intracellular content of
glutamine is decreased [81]. The decrement in intracellular
pool of glutamine may impair leucine transport to inside the
cell. On the other hand, the increase of glutamine transport
outside the cell may favor the entry of leucine into the cell. If
leucine transport is stimulated, the ﬁnal result of catabolism
could increase the availability of glutamine to the cell
through glutamate. However, there are no studies evaluating
the eﬀects of leucine and glutamine supplementation under
inﬂammatory conditions.
BCAA can indirectly modulate the inﬂammatory status
of muscle cells through glutamine production but this reac-
tionappearstooccuronlyinsituations characterizedbyhigh
glutamineconsumptionand/ordecreasedglutamateconcen-
trations (i.e., catabolic illnesses, cancer, burning, and sepsis).
Glutamine is an amino acid that plays an important
role in maintaining cell function. Ehrensvard et al. [82]
ﬁrst described the importance of glutamine to survival and
proliferation of cells such as kidney, intestine, liver, speciﬁc
neurons in the central nervous system (CNS), pancreatic β
cells, and cells of the immune system. It is widely known
that cells of the immune systemsuchas lymphocytes, macro-
phages, and neutrophils use high rates of glutamine and
many functional parameters of immune cells such as T-
cell proliferation, B-lymphocyte diﬀerentiation, macrophage
phagocytosis, antigen presentation, and cytokine produc-
tion, plus neutrophil superoxide production and apoptosis
are enhanced by glutamine. Under pathological conditions,
which increase the activity of these cells glutamine is ex-
tremely used as substrate [83–85].
It has already been demonstrated that the availability of
glutamine inﬂuences the production of cytokines such as
interleukin-(IL-)2inculturedrodentlymphocytes[86]and,
IL-2, IL-10, and interferon-γ (IFN-γ) in cultured human
lymphocytes [87, 88]. Studies have also demonstrated that
glutaminemayplayanimportantroleonNF-κBsignaltrans-
duction pathways, contributing to the attenuation of local
inﬂammation [89–92]. When inhibited in the cytoplasmJ o u r n a lo fN u t r i t i o na n dM e t a b o l i s m 5
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Figure 2: Possible role of glutamine as an intermediary of BCAA action on skeletal muscle inﬂammation. BCAA could modulate
inﬂammatory response through glutamine synthesis. Such reaction occurs through BCAA transamination and generation of glutamate from
α-KG. Glutamate is then converted to glutamine by glutamine synthetase. α-KG: alpha-ketoglutarate; α-KIC, α-ketoisocaproate; BCAA:
branched-chain amino acids; GDH: glutamate dehydrogenase.
NF-κB is bound to an inhibitory protein: IκB. In inﬂamma-
tory conditions, the IκBs are phosphorylated by the action
of speciﬁc protein kinases, such as the IKB kinase complex
(IKK) at two serine residues with addition of ubiquitin by
ubiquitin ligase and degraded by 26S proteasome complex
resulting in liberation of NF-κB. Activated NF-κB then binds
to the cognate DNA-binding sites inducing gene transcrip-
tion that regulates the innate and adaptive immune response
(i.e.,T-celldevelopment,maturation,andproliferation)[93–
95].
Regarding skeletal muscle remodeling, NF-κBa c t sa s
F o X O ,at r a n s c r i p t i o nf a c t o ro fM u R F - 1g e n ew h i c hp r o -
motessarcomericdegradationbyUPS[62].Severalcytokines
also have their gene expression modulated by NF-κB( i . e . ,
TNF-α and IL-1β). It was demonstrated that IL-1β presents
signiﬁcant correlation with skeletal muscle cross-sectional
area and, therefore, can be considered as an atrophic
modulator [96]. NF-κB also promotes the transcription of
the inducible isoform of nitric oxide synthase (iNOS) [97]
which leads to insulin resistance through nitrosylation of
the insulin receptor (IR) [98]. Under such conditions, the
mTOR translation pathway has impaired signal transduction
through proteins involved in translation initiation such as
insulin receptor substrates (IRS), Akt, and 4E-BP1 [18].
Therefore, inﬂammation may modulate muscle remodeling
through both synthetic and catabolic pathways.
Counteracting such eﬀects, BCAA (especially leucine)
has demonstrated to be a strong nutritional stimulus able
to increase skeletal muscle protein synthesis and attenuate
protein degradation. For example, Hamel et al. [99]d e m o n -
strated that leucine presents one of the strongest inhibitory
eﬀectsupon UPSin muscle cellswhencompared to the other
essential amino acids (for details about the antiproteolytic
eﬀects of leucine, please see Zanchi et al. [8]a n dN i c a s t r o
et al. [9]. Furthermore, it has already been demonstrated
that BCAA can stimulate the phosphorylation of proteins
involved in the mTOR pathway such as Akt, mTOR, 4E-BP1,
eIFs, p70S6k in order to improve the protein turnover of
the cell [100, 101]. Since BCAA do not present kinase nor
phosphatase activity, their eﬀects appear to be mediated by
hVpS34 and calcium-related proteins [102].
Thus, BCAA can directly modulate the protein turnover
of the muscle cell in order to counteract the catabolic and
anti-anaboliceﬀectsoftheinﬂammatorystimulus.Addition-
ally, under pathological conditions, BCAA may inﬂuence the
inﬂammatory status of the cell through glutamine produc-
tion. However, this reaction appears to occur only in situa-
tions characterized by a high need of glutamine synthesis.
4 .AP o s s i b l eL i n kb e t w e e nO x i d a t i v eS t r e s sa n d
BCAA-MediatedInﬂammatory Effects
Skeletal muscle cells continuously produce reactive oxygen
species (ROS), which can be generated by various cell
organelles and enzymes, such as mitochondria, NAD(P)H
oxidases, xanthine oxidoreductases, and nitric oxide syn-
thases, whereas their biological activity is opposed by an
array of endogenous enzymatic and nonenzymatic antiox-
idants [103]. Normally ROS play important physiological
roles in skeletal muscle homeostasis and function [104, 105].
However, a disturbance in the state of the well-balanced con-
trol of oxidant production and antioxidant activity, known
as oxidative stress, in turn, is commonly observed during
aging and is characteristic of several pathological conditions6 J o u r n a lo fN u t r i t i o na n dM e t a b o l i s m
such as cancer, diabetes, muscle disuse, sepsis, and chronic
heart failure [106]. It has been reported that this oxidative
stress directs muscle cells into a catabolic state and that
chronic exposure leads to wasting [107]. Oxidative damage
may contribute to skeletal muscle dysfunction [108]a n d
oxidants may stimulate expression and activity of skeletal
muscle protein degradation pathways [38, 109].
There are several evidences showing that the generation
of ROS is one mechanistic link between inﬂammation and
skeletal muscle dysfunction and degradation. ROS produced
by inﬁltrating immune cells may cause direct injury to
muscle tissue or activate catabolic signaling. Alternatively,
inﬂammatory cytokines can interact with muscle receptors
to initiate catabolic signaling wherein ROS are key mediators
of this response, acting as second messengers [107, 110,
111]. Accordingly, overexpression of TNF-α in transgenic
mice [112] and single intraperitoneal doses of this cytokine
[103] promotes muscle wasting that can be attenuated by
antioxidants [103, 108]. On the other hand, ROS activate
transcription factors (e.g., NF-κB and AP-1) and upregulate
expression of proinﬂammatory genes such as TNF-α,I L - 6
and C-reactive protein, which are involved in the pathogene-
sis of inﬂammation [113, 114].
Although administration of BCAA has been investigated
as a tool that could exert an anti-inﬂammatory role or
indirectly modulate the inﬂammatory status in order to
favor the biological response and tissue adaptation, less is
known about the relationship between this strategy and
oxidative stress modulating skeletal muscle structure and
function. There are some emerging reports describing that
ROSmodulatetheeﬃciencyandeﬀectivenessoftheadaptive
responses of skeletal muscle induced by some BCAA, espe-
cially leucine [115, 116]. Regarding BCAA supplementation
and oxidative stress, an interesting study [117] has shown
that this nonpharmacological strategy increases expression
of genes involved in antioxidant defense and reduces ROS
production in cardiac and skeletal muscles in middle-aged
mice, which was accompanied by preserved skeletal muscle
ﬁber size, enhanced physical endurance and increased aver-
age life span. Of interest, BCAA-mediated eﬀects were even
more remarkable in middle-aged mice submitted to long-
term exercise training (running 30 to 60min 5 days/week
for 4 weeks). In young animals (4–6 months old), BCAA
supplementation was ineﬀective.
Aging has been described as a condition characterized
by anabolic resistance to nutrients, especially amino acids,
which impairs muscle protein synthesis and contributes to
muscle wasting. Such resistance is partially associated to
oxidative stress and low-grade inﬂammation and may be
attenuated by chronic anti-inﬂammatory treatment. Recent-
ly, Smith et al. [118] demonstrated that older adults who
received omega-3 fatty acids for 8 weeks increased the hy-
peraminoacidemia-hyperinsulinemia-induced muscle pro-
tein synthesis when compared to the control group (corn
oil), which was accompanied by greater phosphorylation
of mTORSer2448 and p70S6k
Thr389. Furthermore, the authors
observed decreased serum levels of TNF-α in the omega-
3-supplemented group. Therefore, the anti-inﬂammatory
action of nutrients such as omega-3 may attenuate anabolic
resistance in order to favor amino acid-induced muscle
protein synthesis.
ConcerningBCAAsupplementation,Marzanietal.[115]
demonstrated that old rats supplemented with leucine and
with an antioxidant mixture (rutin, vitamin E, vitamin A,
zinc, and selenium) showed higher protein synthesis when
compared to old-control animals and that these eﬀects could
be mediated through a reduction in the inﬂammatory state,
which decreased with antioxidant supplementation. Under
inﬂammatory conditions, such as aging, anabolic resis-
tance occurs mainly because of elevated proinﬂammatory
cytokines. Thus, antioxidant supplementation may attenuate
anabolic resistance and therefore favor leucine action on
skeletal muscle protein turnover.
5. Conclusion andPerspectives
BCAAs present unique features in skeletal muscle protein
metabolism. It is well accepted that their catabolic reactions
can be easily modulated through alterations in metabolic
demands, such as in inﬂammatory status. However, it is
unknown if BCAA can directly modulate the status of
proteins involved in inﬂammatory pathways and if this eﬀect
could reﬂect on protein turnover. Since glutamine is highly
consumed by inﬂammatory cells, it appears to be a mediator
of BCAA and inﬂammation but this reaction is dependent
of glutamate content and GDH activity in skeletal muscle.
FuturestudiesshouldaddresstheeﬀectsofBCAA,glutamine
and the amino acids transporter activity under proinﬂam-
matory conditions.
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